STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Rhea-AI Summary

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 1:30 p.m. PT (4:30 p.m. ET). The presentation will be accessible via a live webcast on the company’s website, with a replay available within approximately 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for diseases with significant unmet medical needs, featuring assets like ARCALYST®, KPL-404, and mavrilimumab, which aim to address underserved conditions by modulating immunological pathways.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST®, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com


FAQ

When is Kiniksa's presentation at the J.P. Morgan Healthcare Conference?

Kiniksa's presentation is on January 9, 2023, at 1:30 p.m. PT (4:30 p.m. ET).

Where can I watch Kiniksa's presentation?

The presentation will be available via a live webcast on Kiniksa's website.

What time will Kiniksa's presentation start?

Kiniksa's presentation will start at 1:30 p.m. Pacific Time.

What company is presenting at the J.P. Morgan Healthcare Conference?

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) is presenting.

What is Kiniksa Pharmaceuticals focused on?

Kiniksa specializes in developing therapeutic medicines for diseases with significant unmet medical needs.
Kiniksa Pharmaceuticals International, plc

NASDAQ:KNSA

KNSA Rankings

KNSA Latest News

KNSA Latest SEC Filings

KNSA Stock Data

3.22B
43.64M
3.74%
92.97%
3.65%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United Kingdom
LONDON